For research use only
| Cat No. | ABL-TC0657 |
| Product Type | Human Leukemia Cell Lines |
| Cell Type | Lymphocyte-like |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Bone Marrow |
| Disease | Acute Lymphoblastic Leukemia |
| Product Code | TALL 1; TALL1; T-ALL-1; T-ALL 1; T-ALL1; T-cell Acute Lymphoblastic Leukemia-1 |
TALL-1 human leukemic T-cell line with lymphoblast morphology, suspension growth, expresses T-cell markers CD2, CD4, CD7, CD8, EBV genome negative.
TALL-1 is a human T-cell acute lymphoblastic leukemia (T-ALL) cell line that was originally isolated from the bone marrow of a 28-year-old East Asian male patient with leukemic phase of T-cell lymphosarcoma. The cells exhibit lymphoblast‑like morphology and grow in suspension culture, forming both spherical and rod‑shaped aggregates. TALL‑1 cells express surface markers characteristic of T lymphocytes, including CD2, cytoplasmic CD3, CD4, CD7, and CD8. Karyotypic analysis often reveals chromosomal abnormalities such as NOTCH1 mutations or CDKN2A deletions, which are common in T-ALL. TALL-1 cells demonstrate high tumorigenicity in immunodeficient mice. Their gene expression profile includes upregulated oncogenes (e.g., MYC, TAL1) and dysregulated signaling pathways, making them valuable for studying leukemia progression and drug resistance.
| Product Code | TALL 1; TALL1; T-ALL-1; T-ALL 1; T-ALL1; T-cell Acute Lymphoblastic Leukemia-1 |
| Species | Human |
| Cat.No | ABL-TC0657 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocyte-like |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Bone Marrow |
| Disease | Acute Lymphoblastic Leukemia |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Leukemia Cell Lines |
The TALL-1 cell line offers a valuable resource for researchers delving into the features and chemosensitivity of human leukemic T-cells. Its application extends to exploring pivotal elements in the advancement and progression of lymphoid malignancies, particularly T-ALL, shedding light on underlying mechanisms. Additionally, it aids in identifying essential genes in the molecular pathogenesis of human T-ALL, thereby offering insights into potential strategies for targeted therapeutic interventions.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
